VanEck Associates
MRNA icon

VanEck Associates’s Moderna MRNA Stock Holding History

VanEck Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Sell
200,116
-46,315
-19% -$2.4M 0.01% 530
2026
Q1 		$12.5M Buy
246,431
+18,397
+8% +$858K 0.01% 530
2025
Q4 		$6.72M Sell
228,034
-42,622
-16% -$1.16M 0.01% 690
2025
Q3 		$6.99M Sell
270,656
-25,824
-9% -$720K 0.01% 653
2025
Q2 		$8.18M Buy
296,480
+1,895
+0.6% +$49.9K 0.01% 550
2025
Q1 		$8.35M Buy
294,585
+31,173
+12% +$1.11M 0.01% 537
2024
Q4 		$11M Sell
263,412
-3,517
-1% -$168K 0.01% 443
2024
Q3 		$14.3M Buy
266,929
+114,769
+75% +$10.5M 0.02% 375
2024
Q2 		$18.1M Sell
152,160
-81,086
-35% -$10.3M 0.03% 300
2024
Q1 		$24.9M Sell
233,246
-37,528
-14% -$3.78M 0.04% 240
2023
Q4 		$26.9M Buy
270,774
+43,646
+19% +$3.67M 0.05% 201
2023
Q3 		$23.5M Buy
227,128
+24,698
+12% +$2.75M 0.05% 211
2023
Q2 		$24.6M Buy
202,430
+9,552
+5% +$1.27M 0.05% 211
2023
Q1 		$29.6M Buy
192,878
+15,285
+9% +$2.52M 0.07% 192
2022
Q4 		$31.9M Sell
177,593
-31,887
-15% -$5.21M 0.08% 182
2022
Q3 		$24.8M Buy
209,480
+13,342
+7% +$2.02M 0.07% 197
2022
Q2 		$28M Sell
196,138
-102,523
-34% -$14.7M 0.07% 208
2022
Q1 		$51.4M Buy
298,661
+965
+0.3% +$162K 0.11% 174
2021
Q4 		$75.6M Buy
297,696
+105,382
+55% +$30.8M 0.17% 132
2021
Q3 		$74M Buy
192,314
+36,282
+23% +$13.4M 0.19% 129
2021
Q2 		$36.7M Sell
156,032
-68,988
-31% -$12.3M 0.09% 190
2021
Q1 		$29.5M Buy
225,020
+54,419
+32% +$7.89M 0.08% 185
2020
Q4 		$17.8M Sell
170,601
-181,467
-52% -$18.4M 0.05% 219
2020
Q3 		$24.9M Sell
352,068
-12,554
-3% -$875K 0.08% 157
2020
Q2 		$23.4M Sell
364,622
-85,492
-19% -$4.68M 0.08% 166
2020
Q1 		$13.5M Buy
+450,114
New +$10.4M 0.07% 181

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

VanEck Associates's MRNA Position: Q2 2026 in Review

VanEck Associates reduced its Moderna (MRNA) stake by 19% in Q2 2026, selling an estimated $2.4M and leaving 200,116 shares worth $14M. The position accounts for 0.01% of the portfolio, ranked #530.

VanEck Associates first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $75.6M in Q4 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • VanEck Associates held 200,116 shares of Moderna worth $14M as of Q2 2026.
  • VanEck Associates sold 46,315 Moderna shares in Q2 2026, an estimated $2.4M.
  • Moderna made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #530 holding.
  • VanEck Associates first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • VanEck Associates's Moderna position peaked at $75.6M in Q4 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.